More than 600 pounds of unwanted medications collected in Springfield during National Prescription Drug Take Back Day
Residents cleaned out their medicine cabinets and dropped off any old medications during the Drug Take Back Day event held on Saturday at Central High School. The national event is meant to safely dispose of unwanted or expired medications and make sure they never end up in the wrong hands.
Local officials run drop-off sites on National Prescription Drug Take Back Day
According to the DEA, the majority of teenagers abusing prescription drugs get them from family, friends, or a medicine cabinet at home. The most important part of these events is to remind the public that there is a safe way of disposal.
On Saturday, Springfield Police, along with the Drug Enforcement Administration (DEA) and Hampden County Sheriff's Department, collected 608 pounds of unused or expired medications. If you were unable to drop off your unused or expired drugs on Saturday, there are year-round drop-off locations across western Massachusetts.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 days ago
- The Hill
Safeguarding lives: The urgent need for congressional action on illicit Xylazine
America's opioid epidemic has entered a new and especially dangerous phase, as synthetic fentanyl and deadly additives devastate families and communities across the country. Congress must act now to equip law enforcement with the resources and tools they need to keep communities safe, while preventing unintended consequences on hardworking veterinarians, farmers and ranchers. Today, foreign manufactured, illicit fentanyl and fentanyl-related substances drive the opioid epidemic. Despite being 50 to 100 times stronger than their prescription counterparts, these synthetic opioids are often mixed with toxic cutting agents to increase potency and street value, while decreasing production costs. In recent years, cartels and criminal organizations have increasingly used xylazine, a powerful veterinary sedative, as a low-cost cutting agent for illicit fentanyl. This lethal combination is known as 'tranq.' Designated as an emerging threat to the United States in 2023, illicit xylazine poses grave health and safety risks when ingested by humans, including depressed breathing and heart rate, unconsciousness, severe necrosis and death. As of 2022, the Drug Enforcement Administration had seized xylazine and fentanyl mixtures in 48 states. At the same time, licit xylazine has been approved by the Food and Drug Administration for veterinary use since 1972 and remains a critical tool for veterinarians, farmers and ranchers. They use this drug to treat livestock and wildlife. In cattle, xylazine is the only safe and effective drug. There is no alternative. Currently, the DEA is in the process of making xylazine a controlled substance; however, scheduling xylazine without protecting its legitimate use may limit veterinary professionals' ability to treat animals and could increase the risk of supply disruption. Further, given xylazine is a low-volume, low-margin, generic animal drug, high regulatory burdens could force the few remaining domestic manufacturers to discontinue production altogether. Congress must fight the spread of illicit xylazine while preserving its veterinary use. That's why, over the last two years, we've worked with congressional colleagues, federal agencies and stakeholders like the American Veterinary Medical Association to craft a solution that achieves both goals, titled the Combating Illicit Xylazine Act. Our bipartisan, bicameral bill classifies xylazine as a Schedule III drug under the Controlled Substances Act, and contains several statutory provisions to preserve veterinary professionals' access and provide the DEA transparency into xylazine's market. This added market transparency would allow law enforcement to better track the legitimate sales of xylazine, as well as how the drug is diverted to the black market or illegally imported from China. Last Congress, language containing core components of the Combating Illicit Xylazine Act passed the House of Representatives with overwhelming bipartisan support. This Congress, we reintroduced the bill with updated language to strengthen its provisions. Our legislation is supported by the DEA, multiple law enforcement organizations, including the National Fraternal Order of Police, the National Association of Attorneys General and 30 state attorneys general, and all 50 state veterinary medical organizations. Attorney General Pam Bondi also advocated for the scheduling of xylazine on her first day in office. More than half of states have passed, proposed or implemented xylazine-related legislation or regulations. Passing the Combating Illicit Xylazine Act would alleviate this growing patchwork of state-by-state xylazine restrictions. Congressional inaction would compromise the DEA's ability to effectively combat the ongoing drug epidemic and weaken the nation's public health infrastructure. The Combating Illicit Xylazine Act is a commonsense solution that will help keep deadly xylazine off the streets, without threatening the livelihood of farmers and ranchers nationwide. We urge our colleagues in Congress to join us in support of this legislation and work swiftly to pass it into law.
Yahoo
2 days ago
- Yahoo
US health officials crack down on kratom-related products after complaints from supplement industry
WASHINGTON (AP) — U.S. health officials are warning Americans about the risks of an opioid-related ingredient increasingly added to energy drinks, gummies and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical, known as 7- hydroxymitragynine, is a component of kratom, a plant native to Southeast Asia that has gained popularity in the U.S. as an unapproved treatment for pain, anxiety and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying it as a dangerously concentrated, synthetic form of the original ingredient. The FDA action 'is not focused on natural kratom leaf products," according to a statement Tuesday by the U.S. Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. '7-OH is an opioid that can be more potent than morphine," said FDA Commissioner Marty Makary. "We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A national ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA "demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements. In recent years, the association has lobbied at the state level for bills that limit synthetic 7-OH products. On Tuesday, a rival group that supports the availability of 7-OH drugs criticized the government's move, pointing to the influence of kratom suppliers. 'Big kratom trade groups have spent years blaming 7-OH for harms caused by their own unregulated products, because it threatens their market share,' the Holistic Alternative Recovery Trust stated in an emailed message. Nearly a decade ago, the federal government came close to banning kratom. In 2016, the DEA announced plans to add it to the government's most restrictive schedule 1, reserved for drugs that have no medical use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Matthew Perrone, The Associated Press
NBC News
3 days ago
- NBC News
FDA asks Justice Department to classify gas station products with opioid-like effects as illicit substances
The Food and Drug Administration on Tuesday recommended classifying 7-OH, a compound with opioid-like effects found in unregulated tablets, gummies and drink mixes sold in gas stations and convenience stores, as an illicit substance. Such a move by the Justice Department would restrict or prohibit access to the products, which are also currently sold online. The chemical, formally known as 7-hydroxymitragynine, is often marketed as a way to help people relax, relieve pain or improve their mood or focus. But studies suggest it's more potent than morphine, and the FDA has warned it could damage the heart or liver and potentially lead to seizures, digestive issues, shallow breathing, withdrawal symptoms or even death. 'We've seen a disturbing rise in reports of overdoses, poisonings and emergency room visits linked to products containing 7-OH,' Jim O'Neill, deputy secretary of the U.S. Department of Health and Human Services, said at a press conference Tuesday. He said 7-OH products are often sold without warnings or control over the quality or dosage. 'This is a recipe for public health disaster,' O'Neill said. 7-OH is found naturally in the leaves of a tropical evergreen tree. An herbal extract made from those leaves, known as kratom, is also sold as an unregulated dietary supplement. Kratom products contain trace amounts of 7-OH, whereas products sold under the name '7-OH' contain a synthetic, concentrated version of the chemical, according to the FDA. Sometimes, 7-OH products are misleadingly marketed as kratom. The FDA's recommendation Tuesday will trigger a review from the Drug Enforcement Administration, the branch of the Justice Department responsible for classifying drugs as controlled substances. There are five potential classifications, corresponding to varying degrees of regulation. They're based on a substance's medical use, public health risks and potential for abuse. FDA Commissioner Martin Makary said Tuesday that the FDA is recommending that 7-OH be classified as a Schedule I substance, meaning it has no accepted medical use and a high potential for abuse. Other drugs in that class include heroin, marijuana and ecstasy. The FDA currently warns people not to use kratom products due to the risk of serious side effects such as seizures and liver toxicity, and because it may lead to substance use disorder. The DEA in 2016 said it planned to regulate the active ingredients in kratom, including 7-OH, as Schedule I substances. But the agency nixed the effort after considerable pushback from kratom advocates. Around 1.9 million people ages 12 and up in the U.S. reported using kratom in 2022, according to the National Survey on Drug Use and Health. Tom Prevoznik, an assistant administrator at the DEA, said at Tuesday's press conference that the public will again have an opportunity to comment before a final decision is made. 'DEA will do what we've always done: follow science, follow the law and do what's right to keep our community safe,' he said. Health and Human Services Secretary Robert F. Kennedy Jr. recalled the availability of heroin fueling his own addiction decades ago, and expressed concern about the widespread distribution of 7-OH products near schools, military reservations and in low-income neighborhoods in the United States. He added that 7-OH products are 'marketed for children. They're gummy bears, they're bright colors, they're candy flavored. This is really a sinister, sinister industry.' The FDA issued warning letters in late June to seven companies, which it said were illegally marketing products containing 7-OH. According to the agency, the chemical cannot be lawfully added to conventional foods or dietary supplements because there is not enough information to demonstrate its safety. Dietary supplements don't require FDA approval to be sold or purchased, but the agency mandates that companies that manufacture, package, label or store supplements test their ingredients and limit contamination. It's up to the FDA to test products and determine whether they're unsafe before the agency can remove them from the market. Makary said Tuesday that the FDA is focused on 7-OH rather than kratom, noting that the agency's recommendation distinguishes trace amounts of 7-OH from synthetic, concentrated amounts. 'We are going after the killer first,' he said. The Holistic Alternative Recovery Trust, which advocates for the use of plant-based compounds to address opioid addiction, said the FDA's recommendation Tuesday disregards how 7-OH is used in the real world. 'If 7-OH posed the kind of urgent danger that would justify emergency action, evidence would have been presented. It was not,' Jeff Smith, the group's national policy director, said in a statement. Proponents of kratom say it's useful for pain management and can help people with substance use disorders wean off more dangerous opioids. The American Kratom Association, which advocates on behalf of kratom users, has said it's not opposed to the FDA regulating kratom products via labels, age restrictions or limiting the concentration of 7-OH. However, it maintains that kratom does not have a high potential for abuse or warrant classification as a controlled substance.
